Holen Sie sich die Stockscreener-App
5.08
9.48%
0.44
Handel nachbörslich:
5.09
0.010
+0.20%
Schlusskurs vom Vortag:
$4.64
Offen:
$4.58
24-Stunden-Volumen:
287.20K
Relative Volume:
1.02
Marktkapitalisierung:
$110.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.59M
KGV:
-1.918
EPS:
-2.6486
Netto-Cashflow:
$-54.27M
1W Leistung:
+29.26%
1M Leistung:
-0.20%
6M Leistung:
-63.53%
1J Leistung:
-36.10%
1-Tages-Spanne:
$4.58
$5.1454
1-Wochen-Bereich:
$3.80
$5.1454
52-Wochen-Spanne:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
5.08 | 101.23M | 0 | -57.59M | -54.27M | -2.6486 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | Herabstufung | Stifel | Buy → Hold |
| 2026-01-28 | Eingeleitet | B. Riley Securities | Buy |
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-12 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-07 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
AARD Technical Analysis & Stock Price Forecast - Intellectia AI
AARD Options Chain — NASDAQ:AARD - TradingView — Track All Markets
AARD Options Volatility — NASDAQ:AARD - TradingView — Track All Markets
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56% - Intellectia AI
Aardvark Therapeutics Shares Plunge After Trial Halt - Intellectia AI
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Finviz
AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Prader-Willi Syndrome Market Size in the 7MM was ~USD 600 million in 2023 and expected to grow by 2034, reveals DelveInsight - Barchart.com
[EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out | NDAQ:AARD | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics (AARD) price target decreased by 43.62% to 18.77 - MSN
Aardvark ups to $150M ATM sale with Piper Sandler (NASDAQ: AARD) - stocktitan.net
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Investors to Connect - ACCESS Newswire
Why Aardvark Therapeutics (AARD) paused late-stage ARD-101 trials after cardiac findings - msn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Insider Monkey
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest - MarketBeat
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
US Stocks Recap: Does Aardvark Therapeutics Inc align with a passive investing strategyWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Heart activity changes prompted pause in trial of ARD-101 in PWS - Prader-Willi Syndrome News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
Decliners Report: Can Aardvark Therapeutics Inc outperform under higher oil prices2026 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Stockholders to Connect - ACCESS Newswire
Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information - Minichart
Jones Trading cuts Aardvark Therapeutics stock price target on trial delay - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
User - The Chronicle-Journal
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com - Investing.com Australia
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating By Investing.com - Investing.com India
AARD Stock Price and Chart — NASDAQ:AARD - TradingView
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating - investing.com
B.Riley cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com South Africa
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics Inc. has officially signed an equity distribution agreement with Piper Sandler. - Bitget
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):